Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0400+0.1000 (+5.15%)
At close: 04:00PM EDT
2.0000 -0.04 (-1.96%)
After hours: 07:42PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close1.9400
Open1.9600
Bid1.9800 x 29200
Ask2.0300 x 4000
Day's Range1.9100 - 2.0900
52 Week Range1.0100 - 2.1550
Volume2,011,608
Avg. Volume2,658,933
Market Cap400.558M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.4900
Earnings DateAug 09, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ADMA Biologics Inc
    Analyst Report: Baxter International Inc.Baxter offers a variety of medical instruments and supplies to caregivers, and the company enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use within care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. The company also offers contract manufacturing services to pharmaceutical companies. The Hillrom transaction has added basic equipment, including hospital beds, to its portfolio, although about half of Hillrom's 2021 revenue came from more digitally connected offerings like its smart beds and Voalte medical communications app.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
Advertisement
Advertisement